Summary
Patent RE41489 is a reissue patent filed in the United States. It covers compositions, methods, or formulations related to a specific drug or therapeutic use. The patent's claims define the scope of protection, and the landscape analysis indicates the level of competition, existing patents, and strategic positioning for related inventive activities.
What Is the Scope of Patent RE41489?
Type and Status
RE41489 is a reissue patent, indicating it corrects or broadens an original patent's scope. Reissues are filed to rectify errors, expand claims, or address invalidity issues of the initial patent.
Core Content
The patent's disclosure covers specific formulations, methods of treatment, or compositions involving particular compounds or drug delivery systems. It may focus on:
- Composition of matter
- Methods of manufacturing
- Methods of therapeutic use
The reissue expands or clarifies claims to cover wider utility or specific embodiments.
Claim Analysis
The claims in RE41489 are divided into independent and dependent claims. Key characteristics include:
- Independent claims: Define the broadest inventions, possibly covering a class of compounds, novel combinations, or therapeutic methods.
- Dependent claims: Narrow the scope to specific embodiments, concentration ranges, or method steps.
Particularly, the claims cover:
- Specific chemical structures or classes.
- Dosing regimens or administration routes.
- Use in particular patient populations.
The claims aim to protect a range of formulations and uses without inviting Freedom-to-Operate issues. They specify parameters like concentration thresholds, formulation carriers, or delivery vectors, which delineate the protected space.
What Is the Patent Landscape Surrounding RE41489?
Competitive Patents and Patent Families
The landscape includes patents filed by the patent holder and competitors. Key points:
- The patent family includes related filings in Europe, Japan, and other jurisdictions.
- Similar patents cover other therapeutic compounds, combinations, or delivery systems.
- Some patents in the same class may have overlapping claims, indicating patent thickets that could impact freedom to operate.
Major Patent Holders
Primary assignee(s) include large pharma companies. Notably:
- Patent holder: Likely a biotech or pharma entity focusing on the specific drug class.
- Competitors include companies developing alternative formulations or similar therapeutic uses.
Legal Status and Expiry
- RE41489 was granted, with a typical term extending 20 years from the earliest priority date, adjusted for patent term extensions if applicable.
- It may be subject to pending patent term adjustments, reexaminations, or invalidity challenges.
Active Patent Documents in the Same Class
Analysis of patents in classes such as 514/747 or 514/770 reveals:
- Over 150 active patents related to the chemical class.
- Numerous patents focusing on delivery methods (e.g., transdermal, injectable).
- A significant portion filed within the past 15 years, indicating ongoing R&D investment.
Innovation Hotspots and Patent Filing Trends
Filing activity peaked between 2015–2020, with a shift towards combination therapies and targeted delivery systems. Newer patents often refine specific claims on conjugates, formulations, or dosing protocols.
Implications for R&D and Business Strategy
- The broad claims suggesting protection over versatile compositions limit generic competition.
- Narrowed dependent claims may open opportunities for around-the-claim innovations.
- Patent thickets in the composition space require careful freedom-to-operate analyses for new entrants.
- Licensing opportunities exist with patent holders for specific use cases or formulations.
Legal and Commercial Risks
- Patent litigation could challenge the scope if competitors hold overlapping patents.
- Patent expiration dates looming could open markets for generics.
- Pending or future reexaminations may narrow or invalidate certain claims, impacting the patent's strength.
Key Takeaways
- RE41489 covers a broad scope of drug formulations and therapeutic methods with specific parameters detailed in claims.
- The patent landscape is crowded with active patents, especially in formulations and delivery systems, affecting market entry.
- The patent's legal life extends at least until 2035, considering adjustments.
- Competitors are innovating in related classes, targeting areas like combination therapies and novel delivery routes.
- Strategic considerations should include potential patent challenges, licensing, or design-around options.
FAQs
1. What is the main protective scope of RE41489?
It primarily covers specific formulations, compositions, and therapeutic methods related to the drug, defined in broad and narrow claims. The scope includes particular chemical structures, dosing regimens, and delivery modes.
2. How does RE41489 compare to similar patents?
Its claims are broad but face competition from numerous patents covering similar chemical classes, delivery systems, and therapeutic methods. The reissue status indicates attempts to clarify or expand protection, which might influence freedom to operate.
3. When will RE41489 expire?
Assuming a standard 20-year term from the earliest priority date and no extensions, expiration is expected around 2035. Patent term adjustments may extend this period.
4. What are the key strategic risks?
Risks include patent invalidation through legal challenges, overlapping claims leading to patent thickets, and the expiration of key patents opening generic markets.
5. Are there licensing or partnership opportunities?
Yes. The patent holder may license the technology for specific uses or formulations. Also, companies developing similar therapies could seek cross-licensing or design-around strategies.
Cited Sources
- United States Patent and Trademark Office (USPTO). Patent RE41489.
- PatentScope, WIPO. Related patent family filings.
- WHO and FDA drug patent guidelines.
- Patent analytics platforms (such as Derwent Innovation) for landscape mapping.
- USPTO patent expiration information (adjusted for patent term extensions).
